Evidence map›Paper›PMID 39707677›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2024

Raman Imaging of Targeted Drug Delivery with DNA-Based Nano-Optical Devices.

Swati Tanwar, Siddhi Date, Linika Goel, Lintong Wu, Arnab Chatterjee, Ishan Barman

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Swati TanwarDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0000-0002-0430-1922
Siddhi DateDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0009-0008-5178-5836
Linika GoelDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0009-0005-2150-2629
Lintong WuDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0000-0003-2534-0768
Arnab ChatterjeeDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0009-0002-9396-2534
Ishan BarmanDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0000-0003-0800-0825

Funding

Wide-Field Short-Wave Infrared (SWIR) multiphoton (MP) tissue imagingP41EB015871 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SO, PETER T. · 2012 to 2021
$11.3M
Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopyR01CA238025 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI RAJARAM, NARASIMHAN · 2019 to 2024
$2.0M
Next-generation optical nanoprobes: From quantum biosensing to cellular monitoringR35GM149272 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ISHAN BARMAN · 2023 to 2026
$1.6M
Air Force Office of Scientific Research FA9550-20-1-0137NCI NIH HHS R01 CA238025NIBIB NIH HHS 2-P41-EB015871- 31NIBIB NIH HHS P41 EB015871NIGMS NIH HHS 1R35GM149272NIGMS NIH HHS R35 GM149272
6 · The paper itself

Abstract

Raman spectroscopy (RS) has emerged as a novel optical imaging modality by identifying molecular species through their bond vibrations, offering high specificity and sensitivity in molecule detection. However, its application in intracellular molecular probing has been limited due to challenges in combining vibrational tags with functional probes. DNA nanostructures, known for their high programmability, have been instrumental in fields like biomedicine and nanofabrication. So far, their ability to customize Raman signals remains largely untapped. In this study, a new class of Raman active DNA origami-based hybrid nanodevice (ND) for targeted cancer cell drug delivery and imaging is engineered. The ND is specifically engineered for metastatic prostate cancer treatment, featuring a legumain enzyme-responsive sequence for the controlled release of the chemotherapeutic agent doxorubicin. Integrating RS with precise targeting, the ND enables imaging of aggressive cancer cells and efficient drug delivery with minimal off-target effects. The developed device offers stimuli-responsive behavior, enhanced stability, exceptional tunability, and potent targeting abilities, positioning it as a highly promising strategy for advancing precision cancer imaging and therapy.

Indexed as

DNA origamienzyme‐responsiveRaman Imagingtargeted cancer therapyvibrational tags

Identifiers

PMID39707677
PMCPMC12179325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.